Who We Are
Dedicated to the eradication of cancer through the development of innovative vaccine technologies, Vaxco Pharmaceuticals has made unprecedented advances in the realm of cancer treatment. Using techniques that have been developed and refined over two decades by our own Chairman and CEO, Raj Sadasivan M.D., Ph.D., Vaxco Pharmaceuticals is pressing forward with its intent to release into the market HCI001, a vaccine therapy that will prove to be a viable treatment for metastatic melanoma.
This vaccine technology has paved the way for an exciting future and brings with it the profound responsibility to efficiently turn our ideas into realities, quickly making vaccine therapies available to the public. It is this sense of responsibility that drives us. It is this sense of responsibility that motivates us, and it is this sense of responsibility that empowers us to change the current state of cancer treatment. Cancer occupies three of the top ten causes of death in the United States, and the sooner our new treatments come to market, the sooner lives can be saved.
Using the knowledge gained from the research of HCI001, Vaxco Pharmaceuticals has developed an exciting pipeline that will change the way we approach cancer. Our research shows that the science behind HCI001 is applicable to other diseases including cancers of the lung, prostate, colon and breast, and as each of these treatments becomes a reality, Vaxco Pharmaceuticals moves one step closer to our goal of making cancer a disease of the past.
In order to meet the needs of the 11 million cancer patients in the United States, Vaxco Pharmaceuticals has assembled a highly qualified team of leaders to usher our company to the forefront of the biopharmaceuticals industry. Because our leadership team and employees work closely together, an uninterrupted interchange of inspiration and creativity enables Vaxco Pharmaceuticals to effectively and efficiently reach those people in need of new, innovative treatments.